BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bautista F, Engelhard D, Rizzari C, Baka M, Saavedra-Lozano J, Lopez-Medina E, Nasmyth-Miller C, Hernández-Sánchez J, Sturm S. Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza. Open Forum Infect Dis 2019;6:ofz430. [PMID: 31660381 DOI: 10.1093/ofid/ofz430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Sturm S, Lemenuel-Diot A, Patel K, Gibiansky L, Bhardwaj R, Smith PF, Dang S, Zwanziger E, Nasmyth-Miller C, Ravva P. Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug-disease modelling for dosing regimen optimization. Br J Clin Pharmacol 2021;87:1359-68. [PMID: 32808306 DOI: 10.1111/bcp.14523] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Zaraket H, Hurt AC, Clinch B, Barr I, Lee N. Burden of influenza B virus infection and considerations for clinical management. Antiviral Res 2021;185:104970. [PMID: 33159999 DOI: 10.1016/j.antiviral.2020.104970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jordie EB, Gibiansky L, Knab T, Lemenuel-Diot A, Ravva P, Zwanziger E, Jolivet S, Bhardwaj R, Hernández-Sánchez J, Nasmyth-Miller C, Sturm S. Dosing regimen optimisation for oseltamivir in immunocompromised paediatric patients with influenza: Extrapolation of efficacy. Br J Clin Pharmacol 2021. [PMID: 34449090 DOI: 10.1111/bcp.15059] [Reference Citation Analysis]